Warner Bros. Discovery has crossed through its June 9 earnings event with the stock little changed on the week, leaving the most interesting story in options positioning rather than short interest.
The clearest shift is in put/call dynamics. The PCR has dropped to 1.96 — nearly 1.6 standard deviations below its 20-day average of 2.15 — meaning options traders are holding far fewer puts relative to calls than they have for most of the past month. That's a meaningful rotation: the PCR peaked near 2.86 in late April, and has been grinding lower through May and into June. The defensive posture that defined positioning through Q1 earnings season has visibly eased. The borrow market reinforces this read — availability is effectively unconstrained, running near the system cap with over 2.4 billion shares available to lend. Short interest is modest at 2.5% of free float, and fell another 4% in the latest session. Cost to borrow has been volatile intraday but remains well below 0.5%. There is no meaningful squeeze pressure in the lending market, and the short base is not an active driver of the story here.
The Street is cautious but not hostile. The consensus is technically a buy, but that overstates conviction — there are just two buy ratings against one sell, with the bulk of recent analyst moves clustered around Hold or Neutral. UBS nudged its target up to $31 in early May after Q1 results; Guggenheim reiterated Neutral around the same time. Before that, Wells Fargo reinstated at Equal-Weight with a $31 target, while Raymond James delivered a sharp double-downgrade to Underperform back in February. The mean target of roughly $31 sits about 17% above the current price of $26.56, but the distribution skews toward caution rather than conviction. Factor scores add texture: EPS momentum ranks in the top percentile over both 30- and 90-day windows, and EPS surprise is in the 98th percentile — both point to results consistently coming in above expectations. Yet forward earnings growth ranks just 11th percentile, and the EV/EBIT factor is near the bottom of the universe, reflecting the debt-heavy balance sheet the bear case centres on. The valuation is not demanding on EV/EBITDA at around 11.6x, but the company is still loss-making on a net basis.
The institutional picture shows the index and passive community firmly anchored. BlackRock holds 7.8% of shares and added nearly a million shares through May. State Street holds 5.1%. The more active names tell a different story — Millennium and Citadel both reported large new positions as of March-end, with Millennium adding 18 million shares and Citadel 17.6 million. Whether those are hedged positions or directional bets is unclear, but their scale relative to a 2.5% short base is notable. The insider activity documented in the previous note — a cluster of senior executives selling in the $27.82–$27.95 range in March, followed by a director selling at $27.20 in April — has not reversed. The stock now trades at $26.56, roughly 4% below those exit prices.
The earnings history offers limited guidance. The May 8 Q1 print produced a muted 0.4% next-day move and then modest drift lower over five days. The structural debate — how fast Max can grow internationally, whether the linear networks segment finds a floor, and what the debt load means for strategic optionality — is unlikely to resolve around any single quarter.
The next formal test is the Q2 earnings event on August 7. Between now and then, the degree to which the PCR continues to normalise toward its historical average — or reverses back toward the heavy put-buying of April — will be the clearest real-time gauge of whether the post-earnings positioning shift is holding.
See the live data behind this article on ORTEX.
Open WBD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
